Carfilzomib

1:39
Phase III ASPIRE study of carfilzomib, lenalidomide and dexamethasone in relapsed myeloma
Jeffery Matous
3:16
Phase III ASPIRE study and prospective anti-CD38 therapy for myeloma
Keith Stewart
5:04
Recent investigational advances in the management of relapsed/refractory myeloma
Paul Richardson
3:48
KEYNOTE-183 trial of pembrolizumab in multiple myeloma: trial design and rationale
Jatin Shah
23:19
12th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2014: Day 2 meeting highlights
Anton Hagenbeek et al.
1:40
Prospective targeted therapies for multiple myeloma
Philippe Moreau
2:01
Results of the ENDEAVOR trial comparing carfilzomib and bortezomib in multiple myeloma
Joseph Mikhael
4:54
Immunomodulators, proteasome inhibitors and monoclonal antibodies for multiple myeloma
Pieter Sonneveld
1:43
ENDEAVOR trial: Carfilzomib and dexamethasone for relapsed multiple myeloma
Jesús San Miguel
5:03
Multiple myeloma clinical trials: What’s hot at ASH 2015?
Mohamad Mohty
3:24
Treatment of relapsed multiple myeloma: New combinations, new generations, new targets
Keith Stewart
1:08
The FORTE clinical trial of carfilzomib in multiple myeloma
Gareth Morgan
2:52
The role of proteasome inhibitors in multiple myeloma
Mohamad Mohty
1:37
Treating patients with relapsed myeloma
Keith Stewart
2:22
Recent drug approvals for the treatment of relapsed/refractory multiple myeloma
Paul Richardson
1:20
Myeloma X and XI trials: outcomes for multiple myeloma patients
Karthik Ramasamy
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals